Phase III trial to assess the efficacy and safety of EscharEx® for debridement and facilitation of active wound closure ...

MediWound , an Israeli developer of products to treat burns and wounds using non-surgical tissue repair, said on Wednesday it was starting a Phase III trial for its treatment for venous leg ulcers.

Phase III trial to assess the efficacy and safety of EscharEx® for debridement and facilitation of active wound closure Interim analysis planned after 65% of patients complete treatment, expected in ...

YAVNE, Israel - MediWound Ltd. (NASDAQ:MDWD), a biopharmaceutical company specializing in enzymatic therapies for tissue repair, has launched a Phase III clinical trial for its product EscharEx®, ...

The Zika virus modifies the chemical composition of human skin, making individuals more attractive to mosquitoes. These ...

Assistant Professor in the School of Biological Science and Medical Engineering at Beihang University. She received her Ph.D.

Dr MKO AbimbolaDiabetes is a long-term condition caused by defi­ciency in quantity or function of insulin, the chemical controlling the level of sugar in the blood. People with diabetes par­ticularly ...

He says: "Contrary to widespread belief, muscle growth is not solely dependent on animal proteins - in fact, relying on plant ...

Newborns with heart complications can rely on their newly developed immune systems to regenerate cardiac tissues, but adults aren't so lucky. After a heart attack, most adults struggle to regenerate ...